Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
FDA’s PreCheck Pilot Program aims to de-risk and accelerate domestic capacity buildouts via earlier regulatory interaction, aligning manufacturing policy with supply-chain resilience priorities.
Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.
Proposed 100% tariffs target branded pharma imports, with a July 31, 2026 window to negotiate onshoring agreements that could reduce the rate to 20%. Exemptions may apply through MFN-negotiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results